Headquartered in San Diego, BioNano Genomics is delivering an altogether better way of gaining a fully informed understanding of genomes. BioNano is the only company that offers a systematic and commercially viable approach to detect the long-range genomic information that reveals the structure of complex genomes, such as human and cancer. Structural variations are increasingly known for being inextricably tied to human diseases and therefore are vital to their diagnosis and treatment. The Company's Irys platform provides researchers and clinicians with the most comprehensive, organized and actionable picture of a genome, including unprecedented insights into how the individual components of genomes are ordered, arranged, and interact with each other. BioNano Genomics works with institutions in life science, translational research, molecular diagnostics and personalized medicine. The Company is supported by Legend Capital, Novartis Venture Fund, Federated Kaufmann Fund, Monashee Investment Management, Domain Associates, Battelle Ventures and Gund Investment as well as grant funding from genomics programs at federal agencies, including the NIH and NIST-ATP.